Literature DB >> 25465302

Heart failure with preserved ejection fraction: refocusing on diastole.

Antonio Abbate1, Ross Arena2, Nayef Abouzaki3, Benjamin W Van Tassell4, Justin Canada5, Keyur Shah3, Giuseppe Biondi-Zoccai6, Norbert F Voelkel7.   

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) is a clinical syndrome of exercise intolerance and/or congestion, in the presence of a left ventricular (LV) ejection fraction within the normal limits (i.e. LVEF>50%). Determining the presence of impaired LV relaxation and/or filling (diastolic dysfunction) in HFpEF is needed to pragmatically to distinguish it from other cardiac and non-cardiac conditions where symptoms are not due to HF. There are multiple mechanisms for diastolic dysfunction ranging from structural abnormalities to functional derangements in HFpEF yet tailored therapies are lacking. Treatments proven effective in HF with systolic dysfunction have failed to show significant benefit in patients with HFpEF, which prognosis remains poor. This review will discuss the challenges inherent to the use of diagnostic criteria for HFpEF, differential diagnosis, prognostic evaluation, and treatment, highlighting the need for more research in this field.
Copyright © 2014. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Cardiopulmonary; Diastole; Exercise; Heart failure; Physiology

Mesh:

Year:  2014        PMID: 25465302     DOI: 10.1016/j.ijcard.2014.11.106

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  35 in total

1.  A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II.

Authors:  Jessica A Regan; Adolfo Gabriele Mauro; Salvatore Carbone; Carlo Marchetti; Rabia Gill; Eleonora Mezzaroma; Juan Valle Raleigh; Fadi N Salloum; Benjamin W Van Tassell; Antonio Abbate; Stefano Toldo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-07-17       Impact factor: 4.733

Review 2.  Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease.

Authors:  Alexander T Mikhailov; Mario Torrado
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 3.  Molecular switches under TGFβ signalling during progression from cardiac hypertrophy to heart failure.

Authors:  J Heger; R Schulz; G Euler
Journal:  Br J Pharmacol       Date:  2015-11-16       Impact factor: 8.739

4.  Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction.

Authors:  Eloy Domínguez; Patricia Palau; Eduardo Núñez; José María Ramón; Laura López; Joana Melero; Alejandro Bellver; Enrique Santas; Francisco J Chorro; Julio Núñez
Journal:  ESC Heart Fail       Date:  2018-03-24

5.  Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction.

Authors:  Salvatore Carbone; Justin M Canada; Leo F Buckley; Cory R Trankle; Dave L Dixon; Raffaella Buzzetti; Ross Arena; Benjamin W Van Tassell; Antonio Abbate
Journal:  J Am Coll Cardiol       Date:  2016-12-06       Impact factor: 24.094

6.  Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF.

Authors:  Amanda K Verma; Jie-Lena Sun; Adrian Hernandez; John R Teerlink; Phillip J Schulte; Justin Ezekowitz; Adriaan Voors; Randall Starling; Paul Armstrong; Christopher M O'Conner; Robert J Mentz
Journal:  Clin Cardiol       Date:  2018-07-17       Impact factor: 2.882

7.  Creation of a restrictive atrial communication in heart failure with preserved and mid-range ejection fraction: effective palliation of left atrial hypertension and pulmonary congestion.

Authors:  Anna Bauer; Markus Khalil; Monika Lüdemann; Jürgen Bauer; Anoosh Esmaeili; Roberta De-Rosa; Norbert F Voelkel; Hakan Akintuerk; Dietmar Schranz
Journal:  Clin Res Cardiol       Date:  2018-04-16       Impact factor: 5.460

Review 8.  Heart Failure With Preserved Ejection Fraction: A Perioperative Review.

Authors:  Sasha K Shillcutt; M Megan Chacon; Tara R Brakke; Ellen K Roberts; Thomas E Schulte; Nicholas Markin
Journal:  J Cardiothorac Vasc Anesth       Date:  2017-08-30       Impact factor: 2.628

9.  IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.

Authors:  Benjamin W Van Tassell; Cory R Trankle; Justin M Canada; Salvatore Carbone; Leo Buckley; Dinesh Kadariya; Marco G Del Buono; Hayley Billingsley; George Wohlford; Michele Viscusi; Claudia Oddi-Erdle; Nayef A Abouzaki; Dave Dixon; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Circ Heart Fail       Date:  2018-08       Impact factor: 8.790

10.  Treating Heart Failure with Preserved Ejection Fraction: A Challenge for Clinicians.

Authors:  Patricia A Howard
Journal:  Hosp Pharm       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.